BIENAIME JEAN JACQUES purchased $10K of KROS
BIENAIME JEAN JACQUES purchased 1,000 shares of Keros Therapeutics, Inc. (KROS) at $10.27 on 2026-08-17 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The purchase adds modest confidence but is unlikely to affect market pricing.
Market read
Low relevance; small insider purchase with limited trading impact.
What to watch
Potential upcoming catalyst (e.g., trial data) could make this purchase more meaningful.
Background
Form 4 filing discloses insider trades; this is the first public report of the purchase.
Ticker impact
Director Jean Jacques Bienaime purchased 1,000 KROS shares at $10.27 each via a 10b5-1 plan, increasing holdings to 19,592 shares.
Minimal impact; price likely unchanged.
The transaction size ($10.3k) is trivial relative to market cap and typical trading volume.
Market effects
None; insider activity does not affect biotech sector outlook.
No regional effect; transaction is localized to the company.
Insignificant on a global scale.
Counterpoint
Even small insider buys can precede positive news; monitor upcoming clinical updates.
Key entities
- CompanyKeros Therapeutics, Inc.
Biotech firm developing therapies for rare diseases.
- InsiderJean Jacques Bienaime
Director of Keros Therapeutics.